Data examining the effect of Neupro (rotigotine transdermal system) in both Parkinson’s disease and restless legs syndrome (RLS) was presented at the 64th American Academy of Neurology Annual Meeting in New Orleans.
Key data presentations focused on post hoc analyses of pivotal and other studies of the rotigotine transdermal system and investigated its impact on the core symptoms of RLS and on the motor and underlying symptoms of Parkinson’s disease such as depression, anxiety, anhedonia, fatigue, and pain.
"These results add to the body of clinical evidence supporting rotigotine transdermal system. The data underscore UCB’s continuing commitment to discovering and developing therapies that address unmet medical needs for potentially debilitating central nervous system disorders,” said Dr James Zackheim, senior medical director, Central Nervous System Business Unit, UCB Inc.
Last month, the US Food and Drug Administration approved Neupro for the treatment of the signs and symptoms of advanced stage idiopathic Parkinson’s disease and as a treatment for moderate-to-severe primary RLS.
